Polyrizon Raises $3.5 Million via Registered Direct Offering and Private Placement

Polyrizon Ltd. ( (PLRZ) ) just unveiled an announcement.

On April 7, 2026, Polyrizon Ltd. entered into definitive agreements with a single institutional investor for a registered direct offering of ordinary shares and pre-funded warrants, alongside a concurrent private placement of additional pre-funded and common warrants. The combined transactions, expected to close on or about April 8, 2026, are set to raise approximately $3.5 million in gross proceeds for general corporate purposes and working capital, and will result in 2,083,939 ordinary shares outstanding assuming full exercise of all pre-funded warrants.

The financings comprise 87,777 ordinary shares and 190,000 pre-funded warrants in the registered direct deal, plus 111,111 PIPE pre-funded warrants and 388,888 common warrants in the private placement, mostly exercisable immediately at a de minimis price for the pre-funded series and $9.00 for the five-year common warrants. The structure, supported by Aegis Capital Corp. as exclusive placement agent and governed by registration and standstill commitments, bolsters Polyrizon’s cash position while introducing potential future dilution as warrants are exercised, a trade-off common among small-cap biotech issuers seeking to fund ongoing R&D and regulatory progress.

More about Polyrizon Ltd.

Polyrizon Ltd. is a pre-clinical-stage biotechnology company developing intranasal protective solutions based on proprietary hydrogel technologies. Its Capture and Contain (C&C) nasal spray platform aims to form a “biological mask” barrier in the nasal cavity against viruses and allergens, while its early-stage Trap and Target (T&T) technology focuses on intranasal delivery of active pharmaceutical ingredients.

Average Trading Volume: 55,984

Technical Sentiment Signal: Sell

Current Market Cap: $17.97M

For an in-depth examination of PLRZ stock, go to TipRanks’ Overview page.